TW201713342A - 以吡嗪羧醯胺化合物為有效成分之醫藥組成物 - Google Patents

以吡嗪羧醯胺化合物為有效成分之醫藥組成物 Download PDF

Info

Publication number
TW201713342A
TW201713342A TW105113124A TW105113124A TW201713342A TW 201713342 A TW201713342 A TW 201713342A TW 105113124 A TW105113124 A TW 105113124A TW 105113124 A TW105113124 A TW 105113124A TW 201713342 A TW201713342 A TW 201713342A
Authority
TW
Taiwan
Prior art keywords
bmx
cancer
compound
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
TW105113124A
Other languages
English (en)
Chinese (zh)
Inventor
Satoshi Konagai
Hiroko Yamamoto
Hideki Sakagami
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of TW201713342A publication Critical patent/TW201713342A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
TW105113124A 2015-04-28 2016-04-27 以吡嗪羧醯胺化合物為有效成分之醫藥組成物 TW201713342A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015092301A JP2018104290A (ja) 2015-04-28 2015-04-28 ピラジンカルボキサミド化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
TW201713342A true TW201713342A (zh) 2017-04-16

Family

ID=57198305

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105113124A TW201713342A (zh) 2015-04-28 2016-04-27 以吡嗪羧醯胺化合物為有效成分之醫藥組成物

Country Status (3)

Country Link
JP (1) JP2018104290A (ja)
TW (1) TW201713342A (ja)
WO (1) WO2016175252A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
EP3533448A4 (en) 2016-10-26 2020-06-10 Astellas Pharma Inc. STABLE PHARMACEUTICAL COMPOSITION
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914682B8 (pt) * 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
WO2014025486A1 (en) * 2012-08-06 2014-02-13 Acea Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
TWI532727B (zh) * 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物

Also Published As

Publication number Publication date
JP2018104290A (ja) 2018-07-05
WO2016175252A1 (ja) 2016-11-03

Similar Documents

Publication Publication Date Title
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
TWI333953B (en) Pyrazolopyrimidines as protein kinase inhibitors
TWI656875B (zh) 藉二氫吡并吡治療癌症
US11311552B2 (en) Therapies for cancer
TW201242598A (en) Combination therapies for hematologic malignancies
TWI655945B (zh) 以二胺基雜環羧醯胺化合物作爲有效成分之醫藥組成物
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
CN102647906A (zh) 三环化合物及其药学用途
CN105461694A (zh) 取代的杂芳基化合物及其组合物和用途
TW201526894A (zh) 藉二氫吡并吡治療癌症
NZ579945A (en) Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
US20200046696A1 (en) Treatment of cancer with smg1-inhibitors
TW201605454A (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW201713342A (zh) 以吡嗪羧醯胺化合物為有效成分之醫藥組成物
WO2017205756A1 (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells
KR20170046193A (ko) 감소된 ｂｒｃａ2 활성을 갖는 암 대상자의 치료를 위한 ｓｎｓ-595의 사용 방법
TW201625254A (zh) 以吡羧醯胺化合物作為有效成分之醫藥組成物
US20210179591A1 (en) New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
JP2017521468A (ja) 組み合わせ療法
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
WO2016029002A2 (en) Growth factor receptor inhibitors
JP2020514345A (ja) 新規な癌の治療法
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
WO2023202563A1 (en) Akt inhibitor in combination with pim kinase inhibitor
TW202202143A (zh) 使用cdk4/6及cdk2抑制劑共同治療以遏止腫瘤對cdk2抑制劑之適應性